In IDH2-mutant AML, the combination of azacitidine and enasidenib vs. azacitidine monotherapy in a phase II study resulted in a significant improvement in response rates (ORR 71% vs. 42%, p < 0.01; CR 53% vs. 12%, p < 0.01) and durations (median DOR 24.1 months vs. 12.1 months, p = 0.05) [29]. This evidence concerns the gene IDH2 and acute myeloid leukemia.